# A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

> **NCT06316531** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 274 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** BL-M07D1
- **DRUG:** T-DM1

## Key facts

- **NCT ID:** NCT06316531
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-08
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06316531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06316531, "A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06316531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*